Novo Nordisk’s Two-Front Data Blitz: Oral Wegovy Scores in Weight Loss as MASH Findings Bolster the Platform
21.05.2026 - 11:44:14 | boerse-global.de
New clinical readouts are giving Novo Nordisk’s flagship molecule a wider medical footprint, even as the stock struggles to shake off a year of heavy losses. Within the span of a few weeks, the Danish drugmaker has unveiled late-stage data for its oral semaglutide pill in obesity and detailed new analyses for the same drug class in fatty liver disease — two closely linked metabolic fronts that together could determine the company’s valuation trajectory.
Oral Semaglutide Delivers a Weight-Loss Breakout — but Only for a Subset
On May 19, at the European Congress on Obesity in Istanbul, Novo Nordisk presented results from the phase 3 OASIS-4 trial testing a 25 mg oral version of semaglutide, the weight-loss drug already marketed as Wegovy in injectable form. Among patients classified as early responders — those who shed at least 10% of their body weight by week 16 — the average weight reduction reached 21.6% over the 64-week study. About one-third of participants qualified for that label.
The mobility gains in that group were twice as large as those seen in the placebo arm. Even patients who missed the early-responder threshold still lost an average of 11.5% of their body weight. The data reinforce the potential of an oral GLP-1 therapy, but the narrow early-responder criterion also underscores the variability in response rates — a nuance that could shape prescribing decisions.
Stock Under Pressure Despite Recovery From Lows
The market’s reaction to the positive data has been muted, reflecting broader headwinds. Novo Nordisk’s shares hover near €38.87, roughly 45% below the 52-week high of €70.13. The stock has bounced more than 27% from its March trough and now sits above its 50-day moving average. On a monthly basis, it has gained about 16%, yet the year-to-date decline remains around 13%.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Competitive pressure is a key drag. Eli Lilly’s oral obesity candidate Foundayo is capturing a growing share of new prescriptions, making the GLP-1 market more crowded and costlier to defend. Novo Nordisk’s 2026 guidance reflects that strain: it expects adjusted sales and operating profit to fall by 4% to 12% in constant currencies, driven by lower U.S. pricing and rising research spending. First-quarter figures showed obesity revenues rising 22% adjusted, but a one-off U.S. effect pushed the overall adjusted top line down 4% on a constant-currency basis.
MASH Data Expand the Medical Case for Semaglutid
From May 27 to 30, the European Association for the Study of the Liver (EASL) congress in Barcelona will provide a new platform for Novo Nordisk’s ESSENCE program, which studies semaglutide in metabolic dysfunction-associated steatohepatitis (MASH). The company plans to release analyses covering liver safety, Japanese patient outcomes, postmenopausal women, and real-world data on disease burden and costs.
The strategic logic is clear. MASH affects an estimated 250 million people globally and overlaps heavily with obesity and type 2 diabetes — the two core markets Novo Nordisk already dominates. The U.S. Food and Drug Administration has already approved Wegovy for MASH in adults with moderate to advanced fibrosis under an accelerated pathway. Interim data from the ESSENCE trial showed that 63% of Wegovy patients achieved MASH resolution without worsening fibrosis, compared with 34% on placebo. Fibrosis improved in 37% of treated patients versus 22% on placebo.
Those findings bolster the argument that semaglutide’s utility extends beyond weight loss into disease modification in the liver — a claim that could support a broader pipeline narrative and potentially cushion the stock against the coming revenue trough.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
Next Catalyst: CagriSema and the Race Against Triple Agonists
Beyond the immediate data events, Novo Nordisk is banking on a combination therapy to close a widening gap with next-generation treatments. In the second half of 2026, the company plans to launch new high-dose studies of CagriSema, a dual amylin and GLP-1 receptor agonist. Management aims to improve overall weight reduction by roughly seven percentage points — enough to match the efficacy seen in rival triple-agonist candidates now in development.
If CagriSema succeeds, the stock’s re-rating may rest on firmer ground than the OASIS-4 or ESSENCE data alone. For now, the EASL congress offers the next concrete test: not of manufacturing capacity or short-term prescriptions, but of whether semaglutide can convincingly occupy a second serious disease territory.
Ad
Novo Nordisk Stock: New Analysis - 21 May
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
